Role of SUMO activating enzyme in cancer stem cell maintenance and self-renewal

Li Du1, Yi-Jia Li1, Marwan Fakih2, Rebecca L. Wiatrek3,†, Marjun Duldulao3,†, Zhenbin Chen3,†, Peiguo Chu4, Julio Garcia-Aguilar3,† & Yuan Chen1

Cancer stem cells (CSCs) have key roles in treatment resistance, tumour metastasis and relapse. Using colorectal cancer (CC) cell lines, patient-derived xenograft (PDX) tissues and patient tissues, here we report that CC CSCs, which resist chemoradiation, have higher SUMO activating enzyme (E1) and global SUMOylation levels than non-CSCs. Knockdown of SUMO E1 or SUMO conjugating enzyme (E2) inhibits CC CSC maintenance and self-renewal, while overexpression of SUMO E1 or E2 increases CC cell stemness. We found that SUMOylation regulates CSCs through Oct-1, a transcription factor for aldehyde dehydrogenases (ALDHs). ALDH activity is not only a marker for CSCs but also important in CSC biology. SUMO does not modify Oct-1 directly, but regulates the expression of TRIM21 that enhances Oct-1 ubiquitination and, consequently, reducing Oct-1 stability. In summary, our findings suggest that SUMOylation could be a target to inhibit CSCs and ultimately to reduce treatment resistance, tumour metastasis and relapse.
Cancer stem cells (CSC) exist in both blood cancers and solid tumours1–3, and present a major obstacle in cancer therapy4. These small populations of cells are capable of growing into new cancers5,6. In addition, CSCs often evade chemotheraphy and radiation (chemoradiation), both of which typically target rapidly dividing non-CSCs. Furthermore, emerging evidence indicates that chemoradiation increases CSC populations7–9, either by eradicating non-CSCs or by inducing dedifferentiation of non-CSCs. CSCs then seed tumour regrowth at the original or a distant site, resulting in tumour relapse and metastasis. Like normal stem cells, CSCs possess long-term self-renewal and multi-lineage differentiation potential. To prevent relapse and metastasis, it is critical to identify molecular targets that regulate CSC maintenance and self-renewal.

Post-translational modification of proteins by the small ubiquitin-like modifier (SUMO) family is frequently dysregulated in cancer and is required for tumour growth and metastasis10,11. SUMOylation involves several steps that are catalysed by three enzymes: SUMO activating enzyme (E1, a heterodimer of SAE1 and SAE2 (also known as Ub-2 subunits); SUMO conjugating enzyme (E2, also known as Ubc9 or UBE2I); and 1 of ~10 E3 ligases12. Briefly, a SUMO protein is first activated by its E1 through ATP hydrolysis, and then forms a thioester conjugate with the E1. SUMO is then transferred to E2, forming a thioester conjugate with E2. Finally, SUMO is transferred to a target protein, a step usually stimulated by an E3 ligase. Ultimately, SUMO modification adds a new docking site to target proteins, and thus enables new protein–protein interactions through the SUMO-interacting motif during signalling events13,14. SUMOylation enzymes are present at higher levels in cancer cells than in normal cells; these high levels are required for tumour progression and metastasis, and are associated with poor survival15,16. However, the role of SUMOylation in CSC maintenance and self-renewal is poorly understood.

In this study, we investigated the role of the SUMO E1 in regulating CSC maintenance and self-renewal. Aldehyde dehydrogenase (ALDH) activity is a widely occurring CSC marker in different cancer types, including solid tumours (for example, colon, lung, liver, bone, pancreatic, prostate, head and neck, bladder, thyroid, brain, melanoma and cervical tumours) and haematological malignancies (for example, acute myeloid leukaemia)17–28. ALDH activity also plays an important role in CSC biology29. We discovered that SUMO E1 and global SUMOylation levels were much higher in CSCs than in non-CSCs of colorectal cancer (CC) cells. Knockdown of SAE2, the catalytic subunit of the SUMO E1, in CSCs reduced their tumour initiation capability in vitro and in xenograft models. Mechanistic investigations revealed that expression of ALDH1A1, an isofrom believed to be critical for CSC function in many cancer types30, was reduced by knockdown of SAE2. We further found that degradation of octamer-binding transcription factor 1 (Oct-1, encoded by POU2F1), the transcriptional activator of ALDH1A1 (refs 31,32), was increased by SAE2 knockdown. This was not through direct Oct-1 SUMOylation; rather, we identified tripartite motif-containing protein 21 (TRIM21) as the ubiquitin E3 ligase for Oct-1. Expression of TRIM21 was increased on knockdown of SAE2, leading to increased Oct-1 ubiquitination and degradation. We verified that TRIM21 expression is dependent on the transcription factor interferon regulatory factor 1 (IRF1), which is regulated by SUMOylation33,34. Therefore, the regulation of Oct-1 stability by SUMOylation is through SUMO-dependent expression of the ubiquitin E3 ligase (that is, TRIM21) that enhances Oct-1 ubiquitin-dependent proteasome degradation. Taken together, we have identified a novel SUMO-dependent mechanism for protein stability control and CSC maintenance. Our findings suggest that SUMOylation, in particular the SUMO E1, may be an effective therapeutic target for inhibiting CSC maintenance and self-renewal.

**Results**

Clinical samples indicates a key role of SUMOylation in CC CSCs. To define which SUMOylation-related proteins have altered expression in CC, we first examined mRNA levels in CC cell lines in comparison with normal colonic mucosa (Supplementary Table 1). We used UCHT116 and HT29 lines, which are representative of major CC types (for example, they have microsatellite instability or are DNA mismatch repair deficient). All of the SUMO-related proteins investigated (SUMO-1, -2 and -3; both SUMO E1 subunits (SAE1 and SAE2/UBA2); Ubc9 (E2, UBE2I); the E3 ligases PIAS1, PIAS2, PIAS3, PIAS4, RanBP2 and MMS21; and de-SUMOylation enzymes SENP1, SENP2, SENP3, SENP5, SENP6 and SENP7) demonstrated increased expression in CC cell lines relative to normal colonic mucosa. The two SUMO E1 subunits, SAE1 and SAE2, were the most highly elevated. To confirm this finding, we examined 27 published gene expression data sets of CC primary tissues; increased SAE2 expression was observed in the majority of studies (Supplementary Fig. 1). To examine the protein levels of the SUMOylation-related proteins, we carried out immunohistochemistry (IHC) on stage II and III colorectal tumour specimens (n = 51) and matched normal tissues (IRB 10132 with patient consent). Our analyses confirmed that SAE2 and SAE1 were more elevated in malignant as compared with normal tissues than the SUMO E3 PIAS1 (Supplementary Fig. 2).

To understand the link between expression of SUMO E1 and CC resistance to chemoradiation, we assessed archived tissues from rectal cancer patients before and after neoadjuvant chemoradiation therapy in a Phase II trial (n = 18) for SUMOylation-related proteins using IHC. Semiquantitative ‘quickscores’ (QS = staining area multiplied by intensity, with values of 0–18) were calculated for IHC specimens. When comparing pre- and post-neoadjuvant chemoradiation tissues from the same patient, there was a significant increase in SAE1 and SAE2 but not PIAS1 (Table 1). This indicates that increased expression of SUMO E1 is associated with CC cells that are resistant to chemoradiation. Because chemoradiation increases the CSC population7–9, higher SUMO E1 levels after chemoradiation suggests its higher levels in CSCs.

**The SUMO E1 is required for CSC maintenance and self-renewal.** To analyse SUMOylation in CC CSCs, we first validated published markers for isolating CSCs. CSC markers reported for CC include CD133, CD44, LGR5 and ALDH activity3,22,35,36. Previous studies also validated HT29 as containing significant amount of CSCs35. ALDH+ and ALDH− HT29 cells were sorted and tested for colony formation in Matrigel-based three-dimensional culture. ALDH+ cells formed colonies but ALDH− cells failed to grow colonies (Fig. 1a and Supplementary Fig. 3). We determined tumour-initiating ability of ALDH+ and ALDH− HT29 cells using in vivo mouse models. Injection of

**Table 1 | Protein levels before and after chemoradiation in 18 patient tumour tissues.**

| SUMO enzyme | Pre-treatment QS | Post-treatment QS | P value |
|-------------|----------------|------------------|--------|
| SAE1        | 4.5 ± 5.7      | 11.9 ± 3.7       | 0.0007 |
| SAE2        | 6.3 ± 4.6      | 12.2 ± 4.4       | 0.0003 |
| PIAS1       | 7.1 ± 2.7      | 5.5 ± 4.5        | 0.26   |

*QS, quickscore (staining area multiplied by intensity, possible range of 0–18); the results shown are the average of readings by two independent pathologists.
ALDH⁺ cells caused tumour growth in all NSG mice tested (3/3), but injection of ALDH⁻ cells failed to grow tumours (0/3) (Fig. 1b). Consistent with CSC characteristics, ALDH⁺ cells were more resistant to radiation than were ALDH⁻ cells (Fig. 1c).

Western blot analysis for ALDH confirmed successful sorting of HT29 and patient-derived xenograft (PDX) primary cells (Fig. 1d). HT29 CSCs (ALDH⁺) expressed greater levels of SAE2 and global SUMOylation than non-CSCs (ALDH⁻) (Fig. 1d and Supplementary Fig. 3d). Interestingly, differences in levels of other SUMOylation-related enzymes, including Ubc9 (Fig. 1d) and PIAS1 (Supplementary Fig. 3b), were less pronounced than differences in SAE2 levels between HT29 CSCs and non-CSCs. Similarly, SENP2 levels are higher in ALDH⁺ than in ALDH⁻ cells, suggesting that ALDH⁺ cells also have enhanced dynamics of SUMO conjugation and deconjugation. To confirm that the results were cell line-independent, we performed the same experiment in primary cultures of PDX CC cells. In PDX primary cultures, higher SAE2 and SUMOylation levels were observed in ALDH⁺ than in ALDH⁻ cells (Fig. 1d and Supplementary Fig. 3d (SUMO-1)).

Figure 1 | Colorectal cancer stem cells have higher SAE2 and global SUMOylation levels than non-cancer stem cells. (a) Representative colony formation assay of ALDH⁺ and ALDH⁻ cells isolated from HT29 cells (scale bar, 50 μm). (b) Tumour development of ALDH⁺ and ALDH⁻ cells isolated from HT29 that were injected in NSG mice (500 cells per mice) subcutaneously. (c) Cell viability assay of ALDH⁺ and ALDH⁻ cells after irradiation (4 Gy) (**P<0.001). (d) Western blot showing ALDH, SAE2, Ubc9 and global SUMOylation (SUMO-2,3) level of ALDH⁺ and ALDH⁻ cells isolated from colorectal cancer cell line HT29 and primary colon cancer PDX tumour tissue (386532 and 354313 correspond to PDX tissues from different patient specimen); GAPDH, loading control.

ALDH⁺ cells caused tumour growth in all NSG mice tested (3/3), but injection of ALDH⁻ cells failed to grow tumours (0/3) (Fig. 1b). Consistent with CSC characteristics, ALDH⁺ cells were more resistant to radiation than were ALDH⁻ cells (Fig. 1c).

To investigate the role of SAE2 in CSCs directly, we performed knockdown of SAE2 in ALDH⁺ cells and carried out LDA in vitro and in vivo. SAE2 knockdown caused reduced colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs. To investigate self-renewal of CSCs, cells from the primary colony were propagated in a secondary colony formation and smaller colony sizes in three-dimensional Matrigel culture, indicating significant impairment of tumour-initiating ability in CSCs.
Identification of TRIM21 as Oct-1 ubiquitin E3 ligase. The mechanism of Oct-1 degradation has not been previously reported. To identify the ubiquitin E3 ligase targeting Oct-1 degradation, HCT116 cells were transfected with Flag-tagged Oct-1 (Oct-1) or empty vector (Ctrl) for 2 days. For this experiment, we used HCT-116 cells, which have higher transfection efficiency than HT29 for producing Flag-tagged Oct-1. Cell lysates were used for immunoprecipitation (IP) with an anti-Flag-tag antibody. After washing, Oct-1 was eluted with an anti-Oct-1 antibody (Fig. 5b). To directly test the effect of SUMOylation on endogenous Oct-1 protein stability, we knocked down TRIM21 in HT29 cells by co-IP with an anti-Oct-1 antibody (Fig. 5b). To directly test the effect of TRIM21 on endogenous Oct-1 protein stability, we knocked down TRIM21 in HT29 cells and observed an increase of Oct-1 ubiquitination-dependent degradation. SUMOylation-dependent Oct-1 degradation is unlikely due to SUMOylation of Oct-1 itself, as we could not observe Oct-1 SUMOylation (Supplementary Fig. 6a).

SUMOylation regulates ALDH through Oct-1. Next we investigated how knockdown of SAE2 reduced ALDH1A1 protein level. We found that knockdown of SAE2 in HT29 cells reduced the protein level of Oct-1, a transcriptional activator of ALDH1A1 and several other ALDH isoforms31,32 (Fig. 4a). Chromosome immunoprecipitation (ChIP) assay showed that the occupancy of Oct-1 at the ALDH1A1 promoter increased by SAE2 overexpression (HT29SAE2) and was reduced by SAE2 knockdown (HT29 shSAE2) (Fig. 4b). These results suggest that SUMOylation regulates ALDH1A1 expression through Oct-1. Knockdown of SAE2 did not reduce Oct-1 mRNA level, indicating that SUMOylation does not directly regulate Oct-1 gene expression (Fig. 4c). However, knockdown of SAE2 increased Oct-1 protein degradation (Fig. 4d). In addition, SAE2 knockdown increased Oct-1 ubiquitination (Fig. 4e). These results indicate that SAE2 knockdown led to increased Oct-1 ubiquitination-dependent degradation. SUMOylation-dependent Oct-1 degradation is unlikely due to SUMOylation of Oct-1 itself, as we could not observe Oct-1 SUMOylation (Supplementary Fig. 6a).

SUMOylation regulates ALDH through Oct-1. Next we investigated how knockdown of SAE2 reduced ALDH1A1 protein level. We found that knockdown of SAE2 in HT29 cells reduced the protein level of Oct-1, a transcriptional activator of ALDH1A1 and several other ALDH isoforms31,32 (Fig. 4a). Chromosome immunoprecipitation (ChIP) assay showed that the occupancy of Oct-1 at the ALDH1A1 promoter increased by SAE2 overexpression (HT29SAE2) and was reduced by SAE2 knockdown (HT29 shSAE2) (Fig. 4b). These results suggest that SUMOylation regulates ALDH1A1 expression through Oct-1. Knockdown of SAE2 did not reduce Oct-1 mRNA level, indicating that SUMOylation does not directly regulate Oct-1 gene expression (Fig. 4c). However, knockdown of SAE2 increased Oct-1 protein degradation (Fig. 4d). In addition, SAE2 knockdown increased Oct-1 ubiquitination (Fig. 4e). These results indicate that SAE2 knockdown led to increased Oct-1 ubiquitination-dependent degradation. SUMOylation-dependent Oct-1 degradation is unlikely due to SUMOylation of Oct-1 itself, as we could not observe Oct-1 SUMOylation (Supplementary Fig. 6a).

Identification of TRIM21 as Oct-1 ubiquitin E3 ligase. The mechanism of Oct-1 degradation has not been previously reported. To identify the ubiquitin E3 ligase targeting Oct-1 degradation, HCT116 cells were transfected with Flag-tagged Oct-1 (Oct-1) or empty vector (Ctrl) for 2 days. For this experiment, we used HCT-116 cells, which have higher transfection efficiency than HT29 for producing Flag-tagged Oct-1. Cell lysates were used for immunoprecipitation (IP) with an anti-Flag-tag antibody. After washing, Oct-1 was eluted with an anti-Oct-1 antibody (Fig. 5b). To directly test the effect of TRIM21 on endogenous Oct-1 protein stability, we knocked down TRIM21 in HT29 cells and observed an increase of Oct-1 ubiquitination-dependent degradation. SUMOylation-dependent Oct-1 degradation is unlikely due to SUMOylation of Oct-1 itself, as we could not observe Oct-1 SUMOylation (Supplementary Fig. 6a).

Identification of TRIM21 as Oct-1 ubiquitin E3 ligase. The mechanism of Oct-1 degradation has not been previously reported. To identify the ubiquitin E3 ligase targeting Oct-1 degradation, HCT116 cells were transfected with Flag-tagged Oct-1 (Oct-1) or empty vector (Ctrl) for 2 days. For this experiment, we used HCT-116 cells, which have higher transfection efficiency than HT29 for producing Flag-tagged Oct-1. Cell lysates were used for immunoprecipitation (IP) with an anti-Flag-tag antibody. After washing, Oct-1 was eluted with an anti-Oct-1 antibody (Fig. 5b). To directly test the effect of TRIM21 on endogenous Oct-1 protein stability, we knocked down TRIM21 in HT29 cells and observed an increase of Oct-1 ubiquitination-dependent degradation. SUMOylation-dependent Oct-1 degradation is unlikely due to SUMOylation of Oct-1 itself, as we could not observe Oct-1 SUMOylation (Supplementary Fig. 6a).

Identification of TRIM21 as Oct-1 ubiquitin E3 ligase. The mechanism of Oct-1 degradation has not been previously reported. To identify the ubiquitin E3 ligase targeting Oct-1 degradation, HCT116 cells were transfected with Flag-tagged Oct-1 (Oct-1) or empty vector (Ctrl) for 2 days. For this experiment, we used HCT-116 cells, which have higher transfection efficiency than HT29 for producing Flag-tagged Oct-1. Cell lysates were used for immunoprecipitation (IP) with an anti-Flag-tag antibody. After washing, Oct-1 was eluted with an anti-Oct-1 antibody (Fig. 5b). To directly test the effect of TRIM21 on endogenous Oct-1 protein stability, we knocked down TRIM21 in HT29 cells and observed an increase of Oct-1 ubiquitination-dependent degradation. SUMOylation-dependent Oct-1 degradation is unlikely due to SUMOylation of Oct-1 itself, as we could not observe Oct-1 SUMOylation (Supplementary Fig. 6a).
ubiquitination of Oct-1, or due to a lack of activity in recombinant TRIM21.

The correlation between Oct-1 and TRIM21 levels was also observed in xenograft experiments. Knockdown of SAE2 reduced Oct-1 and increased TRIM21 protein levels in mouse xenograft tumour tissues as shown by IHC staining (Fig. 6a). This was confirmed by western blots for Oct-1, TRIM21, ALDH and SAE2 in the mice tumour tissues from in vivo LDA (Fig. 6b). Overexpression of SAE2 or Ubc9 decreased TRIM21 promoter activity, while overexpression of SENP1 increased TRIM21 promoter activity, suggesting that SUMOylation suppressed TRIM21 gene expression (Fig. 6c). Consistent with this, TRIM21 mRNA level was suppressed on SAE2 or Ubc9 overexpression but enhanced with SENP1 expression in HT29 cells (Fig. 6d). IRF1, a transcriptional activator of TRIM21 (ref. 33), is SUMOylated at K78 (ref. 39), and previous reports show that its transcriptional activity is suppressed by SUMOylation34. Consistent with the previous finding, the SUMOylated IRF1 band could be observed in ALDH+ and not in ALDH− cells (Supplementary Fig. 7a). A SUMOylation-defective IRF1 mutant K78R induces higher TRIM21 mRNA levels than does WT IRF1, suggesting that SUMOylation suppresses TRIM21 expression (Fig. 6e). Consistent with this, TRIM21 protein levels were suppressed on SAE2 or Ubc9 overexpression but enhanced with SENP1 overexpression in cells (Fig. 6f). In addition, the IRF1-K78R mutant induced higher TRIM21 protein expression than wild-type IRF1 (Fig. 6g). TRIM21 and Oct-1 levels are reversely correlated in both HT29 cell lines and PDX primary cells (Supplementary Fig. 7b). Taken together, our data indicate that inhibiting SUMOylation can increase IRF1 transcriptional activity, which results in increased TRIM21 expression and enhanced ubiquitination and degradation of Oct-1.

To further establish the connection between SAE2 and ALDH1A1 through Oct-1, we investigated whether overexpression of Oct-1 in SAE2 knockdown cells could restore ALDH activity and CSC population and self-renewal. We generated stable cell lines expressing an empty vector or Flag-tagged Oct-1 in HT29 shCtrl and shSAE2 cells (Figs 2 and 7a). The stable lines were confirmed by western blot (Fig. 7b). Overexpression of Oct-1 partially compensated for the effect of SAE2 knockdown in CSC maintenance and self-renewal in in vitro LDA (Fig. 7a and Supplementary Fig. 8). In addition, overexpression of Oct-1 in SAE2 or Ubc9 knockdown cells restored the population of ALDH+ cells (Fig. 7c) and ALDH1A1 protein levels (Fig. 7d) in HT29. The important role of SUMO E1 in CSC maintenance and self-renewal is likely due to the SUMOylation-dependent functions of SAE2, because knockdown of Ubc9 by two independent shRNAs also reduced CSC maintenance and self-renewal, as shown by in vitro LDA (Fig. 7e and Supplementary Fig. 9a). Knockdown of SAE2 or Ubc9 also inhibited cell proliferation (Supplementary Fig. 9b). The regulation of self-renewal is not necessarily related to cell proliferation. LDA in vitro and in vivo was
lysates, followed by western blot with an anti-Oct-1 or anti-ubiquitin antibody. NS, not significant; ***

ubiquitination. HT29 shCtrl or shSAE2 cells were treated with or without proteasome inhibitor MG132 (10 μM) to block protein synthesis in HT29 shCtrl and shSAE2 cells; GAPDH, loading control. Quantification of band intensities (Oct-1 decay curve) in three independent experiments is shown below. (a) Representative western blot showing SAE2 knockdown reduced Oct-1 stability, as shown by treatment with 100 μg ml⁻¹ CHX to block protein synthesis in HT29 shCtrl and shSAE2 cells; GAPDH, loading control. Right panel: quantification of band intensity. (b) SAE2 knockdown did not affect Oct-1 transcription as shown by real-time quantitative PCR measurement of mRNA of HT29 shCtrl and shSAE2 cells. (c) Representative western blot showing SAE2 knockdown reduced Oct-1 stability, as shown by treatment with 100 μg ml⁻¹ CHX to block protein synthesis in HT29 shCtrl and shSAE2 cells; GAPDH, loading control. Quantification of band intensities (Oct-1 decay curve) in three independent experiments is shown below. (d) Representative western blot showing SAE2 knockdown-enhanced Oct-1 ubiquitination. HT29 shCtrl or shSAE2 cells were treated with or without proteasome inhibitor MG132 (10 μM) for 8 h, and IP was carried out using cell lysates followed by western blot with an anti-Oct-1 or anti-ubiquitin antibody. NS, not significant; **P<0.001.

Figure 4 | SAE regulates ALDH expression through controlling Oct-1 stability. (a) Representative western blot of stable HT29 line transduced with shSAE2 lentivirus showed lower Oct-1, ALDH1A1 protein levels than HT29 transduced with control non-silencing shRNA (shCtrl); GAPDH, loading control. Right panel: quantification of band intensity. (b) SAE2 knockdown decreased and SAE2 overexpression increased the occupancy of Oct-1 on the ALDH1A1 promoter as measured by ChIP assay. (c) SAE2 knockdown did not affect Oct-1 transcription as shown by real-time quantitative PCR measurement of mRNA of HT29 shCtrl and shSAE2 cells. (d) Representative western blot showing SAE2 knockdown reduced Oct-1 stability, as shown by treatment with 100 μg ml⁻¹ CHX to block protein synthesis in HT29 shCtrl and shSAE2 cells; GAPDH, loading control. Quantification of band intensities (Oct-1 decay curve) in three independent experiments is shown below. (e) Representative western blot showing SAE2 knockdown-enhanced Oct-1 ubiquitination. HT29 shCtrl or shSAE2 cells were treated with or without proteasome inhibitor MG132 (10 μM) for 8 h, and IP was carried out using cell lysates followed by western blot with an anti-Oct-1 or anti-ubiquitin antibody. NS, not significant; **P<0.001.

Discussion
In this study, we have shown that SUMOylation is critical to CSC maintenance and self-renewal. We have demonstrated that SUMOylation regulates ALDH1A1 expression, a CSC marker that is important for CSC maintenance and self-renewal²⁹,³⁰, through regulating the IRF1-dependent expression of TRIM21 (Fig. 7f). We identified TRIM21 as an ubiquitin E3 ligase that controls the degradation of Oct-1, which is a transcription factor for the expression of ALDH1A1. The important role of SUMOylation in CSC as shown in this study is consistent with a previous study suggesting a positive correlation between global SUMOylation and expression of Lin28, a protein that is highly expressed in stem cells as well as in cancer cells⁴⁰. In addition, SUMOylation is important for normal colon stem cell self-renewal⁴¹, and pathways controlling CSC are often similar to those controlling normal stem cells. The clinical significance of this finding is suggested by the analysis of clinical samples and PDX primary cells (Fig. 1, Table 1 and Supplementary Figs 1–3). Importantly, SUMO E1 level increased after chemoradiation in patient primary CC tumour tissues; such an increase is likely associated with an increase in CSC population and chemoradiation resistance.

Because ALDH activity has been found as a marker for CSCs in many cancer types¹⁷–²⁸, it is likely that our findings are applicable to a broad range of cancers. To investigate this possibility, we isolated ALDH⁺ and ALDH⁻ cells from the breast cancer cell line HCC1937, and found that ALDH⁺ cells had higher levels of SAE2 and global SUMOylation than ALDH⁻ cells. In addition, SAE2 knockdown in HCC1937 cells decreased the population of ALDH⁺ cells (Supplementary Fig. 11).

In this study, we also uncovered a unique mechanism of SUMOylation-dependent regulation of protein stability. SUMOylation regulates Oct-1 stability, not through direct modification of Oct-1, but through altering the expression of its ubiquitin E3 ligase, TRIM21. This SUMOylation-dependent control of a ubiquitin E3 ligase is distinct from the well-established paradigm of SUMO-dependent ubiquitin E3 ligase-induced ubiquitination and proteasome degradation; for example, RNF4, a prototype of such ubiquitin E3 ligases, targets SUMOylated proteins for ubiquitination and proteasome degradation through recognition of poly-SUMO chains⁴²–⁴⁵. Our results revealed a unique mechanism of SUMO-dependent ubiquitination and degradation.

The findings described here expand on previous finding that SUMOylation, and the SUMO E1 in particular, is potentially an important target for developing anticancer therapies¹⁰,¹¹,⁴⁶–⁴⁸. SUMOylation likely affects multiple targets that are important for CSC maintenance and self-renewal. Indeed, we showed that knockdown of SAE2 reduced levels of another colorectal CSC marker, CD44 (Fig. 2b and Supplementary Fig. 5). This likely occurs through a different mechanism than that described here, as CD44 is a target gene of the Wnt-signalling pathway⁴⁹. Previous studies identified key factors in the Wnt-signalling...
pathway as substrates of SUMO modification. Further studies on regulation of Wnt pathway by SUMOylation are required to clarify this interaction. Recent studies also revealed that SUMOylation, in particular the SUMO E1, has a critical role in promoting KRas- and Myc-driven tumorigenesis. Although c-Myc activation contributes to up to 70% of all human cancers, and KRas mutation occurs in more than 50% of all human cancers, drugs inhibiting these oncogenes are not yet available. Our findings suggest that cancer therapeutics targeting SUMOylation could not only inhibit these major oncogenic drivers but also limit CSC growth and self-renewal.

Methods

Patient specimen IHC analysis. Colorectal tumour and matched normal tissue specimens from stage II and III colorectal cancer patients (n = 51) were obtained from biopsy. After chemo and radiation therapy, tumour specimens were obtained from patients without complete pathologic response (non-pCR) (n = 18). Archived specimens from patients with colorectal carcinoma (n = 51), as well as archived normal colorectal tissue were subject to IHC staining using the following antibodies SAE2 (1:200, ab58451, Abcam), SAE1(1:100, ab56957, Abcam) and PIA51(1:300, ab109388, Abcam). Omission of the primary antibody was set as a negative control. IHC staining was evaluated by two independent pathologists who were blinded to patients' clinical outcome. The QS was calculated for each slide based on intensity and percentage of staining area. The intensity of staining was scored semiquantitatively as negative (0), weak (1), intermediate (2) or strong (3). The percentage of staining area was scored as 0–4% (1), 5–19% (2), 20–39% (3), 40–59% (4), 60–79% (5) and 80–100% (6). Two independent pathologists calculated QS by multiplying the intensity score with percentage of staining area and the average score was obtained for each slide. P values were derived using two-tailed Student’s t-test and uncertainties were indicated as s.d. The study was approved by the Research Ethics Board at the City of Hope (IRB # 10132).

Cell lines and PDX primary culture. Colorectal cancer cell lines HT29 and HCT116 (obtained from American Type Culture Collection) were grown in DMEM. Media were supplemented with 10% heat-inactivated fetal calf serum (Omega Scientific, Inc.), 2 mM l-glutamine, 100 U ml⁻¹ penicillin and 100 μg ml⁻¹ streptomycin. Cells were routinely tested by using Mycoalert mycoplasma detection kit (LT07-418, Lonza) to confirm the absence of mycoplasma species.

The PDX model was generated by a subcutaneous implant of human colorectal tumour tissues into NSG mice. The collection of human colorectal cancer tissue was approved by the Research Ethics Board at the City of Hope (IRB13389). Xenograft tumour tissue was washed in PBS, minced and incubated with collagenase (235 U ml⁻¹) and hyaluronidase (850 U ml⁻¹) (Sigma-Aldrich) for 90–120 min at 37 °C. Tumour tissues were minced and re-suspended with 1× ice-cold red blood cell lysis buffer (Santa Cruz Tech) and incubated for 2 min to lyse red blood cells. Cells were then used for further studies. For further separation of cancer cells from stromal or
**Figure 6 | SUMOylation regulates TRIM21 expression through IRF1.** (a) Representative IHC staining indicates higher TRIM21 level corresponding with lower Oct-1 in shSAE2 group tumour tissue compared with shCtrl group (scale bar, 100 μm). Tumour tissues were from LDA assay described in Fig. 2b. (b) Western blot (left) and quantification of SAE2, Oct-1, TRIM21 and ALDH levels in the same tumour tissues as a. GAPDH, loading control. *P<0.05, **P<0.01 and ***P<0.001. (c) TRIM21 promoter activity was inhibited by overexpression of SAE2 and Ubc9 but increased by SENP1 overexpression as determined by luciferase reporter assay. HT29 cells were transfected with empty vector (Ctrl) or SAE2, UBC9 or SENP1 expression plasmid together with TRIM21 promoter luciferase reporter and Renilla plasmids. Dual-luciferase activity was measured after 48h and normalized results were analysed with two-tailed Student’s t-test. (d) TRIM21 mRNA level was suppressed by SAE2 or Ubc9 overexpression and enhanced with SENP1 overexpression in HT29 cells as determined by quantitative PCR (qPCR). (e) IRF1 SUMOylation site mutant K78R induced higher TRIM21 mRNA level than wild-type (WT) IRF1 as determined by qPCR. (f) TRIM21 protein level was suppressed on SAE2 or Ubc9 overexpression but enhanced with SENP1 overexpression as indicated by western blot; GAPDH, loading control. (g) Western blot showed overexpression of K78R mutant-induced higher TRIM21 protein level than WT IRF1 in shCtrl HT29 cells; GAPDH, loading control. *P<0.05, **P<0.01 and ***P<0.001.

**Tumorigenicity in NSG mice.** For the generation of xenografts, cells were injected with Matrigel (BD Biosciences) subcutaneously into flanks of NSG mice (female, 6–8 weeks of age). Mice were monitored for 2 months to observe tumour formation and growth. Animal work was carried out in compliance with the ethical regulations approved by the Animal Regulation Committee, Beckman Research Institute, City of Hope, CA, USA (IACUC#10026).

**Matrigel colony formation assay.** Single-cell suspensions were mixed 1:1 with Matrigel and plated in an eight-well chamber. After 2 weeks of incubation, colony formations were counted and measured using light microscopy (IX81 Olympus). Cells were isolated from colony in matrigel using Corning cell recovery solution (#354253, Corning) and re-seeded with matrigel for secondary colony formation. Colony number and size were counted and measured.

**Lentiviral vectors.** A GIPZ shRNA-eGFP vector with a shRNA sequence targeting the 3’-untranslated region of SAE2 was purchased from GE Dharmacon (CloneId: V2LHS 68112). The GIPZ non-silencing lentiviral shRNA vector was used as a control (shCtrl). Both vectors have green fluorescent protein (GFP) and puromycin resistance markers. Two GIPZ shRNA-eGFP vectors were purchased from GE Dharmacon, one with shRNA sequence targeting the open reading frame of UBC9 (shUBC9#1, Clone ID V2LHS_171776), the other with shRNA sequence targeting the 3’-untranslated region of UBC9 (shUBC9#2, Clone ID V2LHS_171781). pLenti CMV/TO hygro empty (w214-1) vector was obtained from Addgene. Myc-DDK-tagged human Oct-1 (POU2F1) plasmid was purchased from OriGene. DNA coding DDK-tagged Oct-1 was subcloned into pLenti CMV/TO hygro empty vector to make an Oct-1 expression plasmid (pLenti CMV-Oct-1), which was used for viral packaging of the Oct-1 expression construct with hygromycin resistance.

**DNA and RNA transfection.** Transient transfection of plasmid DNA was performed using DNA transfection reagent (Lipofectamine LTX; Invitrogen). siRNA transfection was performed by using Lipofectamine RNAiMAX (Invitrogen). Cells were collected 48h after plasmid DNA transfection and lysed directly in Laemmli sample buffer. After protein quantification, 0.7 μl mercaptoethanol was added to the protein sample, which was boiled at 95°C. For siRNA knockdown, cells were re-transfected with siRNA 72h after the first transfection to ensure siRNA knockdown effects. The cells were then collected 72h after siRNA transfection and either directly lysed in SDS buffer or the RNA was isolated with the microRNAesy kit (Qiagen) according to the manufacturer’s instructions.

**Viral transduction of colorectal cancer cells.** For lentiviral generation, the envelope plasmid pCMV-VSVG and the packaging plasmid pCMV-DR8.2-dprv were obtained from Addgene (8454 and 8455, provided by Dr Bob Weinberg). 293T producer cells were transfected with the lentiviral expression vector and packaging DNA by DNA transfection reagent (Lipofectamine LTX Invitrogen). The supernatant containing lentiviral particles was collected 24–48h after transfection.
Limitation analysis. For LDA in vivo, HT29 cell lines Ctrl-shCtrl and shSAE2 were dissociated into a single-cell suspension and diluted serially to the desired cell doses. Cells were injected subcutaneously into the flanks of NSG mice. Xenografted mice were monitored to up to 2 months to observe tumour formation and growth. Primary tumours from both Ctrl and shSAE2 groups were dissociated into single cells, and EpCAM magnetic sorting was used to isolate cancer cells from stromal cells and fibroblasts. Fluorescence-activated cell sorting analysis confirmed that more than 95% of the isolated cells were EpCAM+ and GFP+. The isolated cells were serially diluted to the desired cell doses and subcutaneously injected into NSG mice for secondary tumour growth. The number of tumours formed out of the number of mice injected was scored to determine the frequency of CSCs, which were calculated using the ELDA software provided by the Walter and Eliza Hall Institute (Melbourne, Australia). The same LDA in vivo study was performed with sorted ALDH+ cells. Briefly, ALDH+ cells from HT29 were transduced with shCtrl (control shRNA) or shSAE2 (shRNA) lentivirus for 3 days. Then cells were injected to NSG mice in a limited dilution series and tumour incidence was monitored for 2 months. CSC frequency was determined and tumour growth curve was measured.

For in vitro LDAs, a single-cell suspension was made and serially diluted to different doses. For each dose, at least 24 wells were seeded with cells. For lower doses, 96 wells were plated at each dose. Four to six weeks later, wells containing spheres were counted, and then the number of positive wells was calculated to estimate sphere formation frequency using the ELDA software. The primary spheres were dissociated to single cells, serially diluted and seeded as above for secondary sphere formation and CSC frequency measurements.

Chromatin immunoprecipitation (ChIP) assay. To detect the occupancy of Oct-1 at the human ALDH1A1 promoter, ChIP analysis was conducted. In all, 2 x 10⁶ cells were incubated in culture medium containing 1% formaldehyde (10 min, room temperature) and the crosslinking reaction was quenched with addition of glycine to a final concentration of 0.125 M. Cells were washed with PBS and collected, followed by sonication to obtain chromatin of primarily mononucleosome size. Fragmented chromatin was then incubated with anti-Oct-1 antibody at 4 °C overnight. Protein–DNA complexes were recovered using protein G agarose beads, washed and eluted with elution buffer. Crosslinks were reversed in 0.2 M NaCl (overnight, 65 °C), and DNA was digested with proteinase K (2 h, 50 °C). The immunoprecipitated DNAs were subsequently isolated and used for PCR. PCR primers specific for the ALDH1A1 promoter were as follows: sense, 5′-GCTTCC TGCCCTAGGTTGA-3′; antisense, 5′-GAACAGGTTGACTGCTA-3′.

Western blot. Cells were lysed with Laemmli sample buffer (5% SDS, 25% glycerol, 150 mM Tris-HCl (pH 6.8) and 0.01% bromophenol blue). After protein concentration was measured by BCA protein assay, 0.7 M β-mercaptoethanol was added and protein samples were sonicated. Protein samples were then separated by SDS–PAGE, and protein was transferred onto a polyvinylidene fluoride membrane (Immobilon-P membrane, Millipore). Specific antibodies to ALDH1A1 (1:1,000, 611194, BD Bioscience), SAE2 (1:1,000, abs85451, Abcam), SUMO-2,3 (1:1,000, #4918, Cell Signaling Technology, Inc.), OCT1 (1:1,000, #8517, Cell Signaling Technology, Inc.), ubiquitin (1:1,000, MAB1510, Millipore), TRIM21 (1:1,000, sc-25351, Santa Cruz), IRF1 (1:1,000, 611194, BD Bioscience), SAE2 (1:1,000, ab58451, Abcam), SUMO-2,3 (1:1,000, #4918, Cell Signaling Technology, Inc.), OCT1 (1:1,000, #8517, Cell Signaling Technology, Inc.), ubiquitin (1:1,000, #8478, Cell Signaling Technology, Inc.), SUMO-1 (1:500, #4930, Cell Signaling Technology, Inc.), SENP2 (1:1,000, sc-67075, Santa Cruz Biotech), PIAS1 (1:1,000, #3550, Cell Signaling Technology, Inc.) and GAPDH (1:1,000, sc-20357, Santa Cruz) were detected using the appropriate secondary antibodies (LiCor) and visualized by Odyssey detection system (LiCor). The uncropped scans of western blots are provided as Supplementary Fig. 12.

Protein degradation assay. Oct-1 protein stability was measured on treatment with protein synthesis inhibitor cycloheximide (CHX). Cells treated with 100 μg/ml CHX (#2112, Cell Signaling Technology, Inc.) were collected at different time points and cell lysate was used for western blot to determine the protein level at different CHX treatment time. Western blot results were quantified by the ImageJ Software (NIH). Three independent experiments were performed and decay curve was plotted.

Co-IP assay. Cells were lysed in RIPA buffer (50 mM Tris-Cl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate and 0.1% SDS) with protease inhibitor cocktail (Catool, EDTA-free, Roche), phosphatase inhibitor cocktail (PhosSTOP, Roche) and 20 mM N-ethylmaleimide (Sigma). After removal of cell debris by centrifugation, 1 μg of the appropriate antibody and 50 μl Protein G agarose dynabeads (Invitrogen) were added to 500 μg of extracted protein and incubated overnight at 4 °C. Beads were washed three times and boiled with 2× SDS loading buffer for western blotting. For detecting Oct-1 and TRIM21 interaction, Clean-Blot IP detection kit (#21323 Thermo Fisher...
Scientific) was used following the manufacture manual to exclude the influence of IgG-fragments heavy chain and light chain.

**Reporter assays.** The TRIM21 promoter (−654 to +1,342) luciferase reporter plasmid was a kind gift from Dr Alexander Espinosa (Weill Cornell Medical College). H1295 cells were transfected with TRIM21 promoter luciferase reporter plasmid, pTK-Renilla normalization plasmid (Promega) and empty vector (Ctrl) or SAE2- or SENP1-encoding plasmids and incubated for 48 h. The Dual-Luciferase Reporter Assay System (Promega) was used to quantify luminescence from transfected cells, and normalized results were analysed with two-tailed Student t-test.

**Reverse transcription–PCR and real-time quantitative PCR.** Total cellular RNA was extracted using RNeasy Mini Kit (Qiagen). Total RNA (2 μg) was reverse transcribed using Omniscript RT Kit (Qiagen) and oligo dT primer. Real-time PCR was performed using the SYBR Green Master Mix (Applied Biosystems) in a 7900HT instrument (Applied Biosystems). The following primers were used for PCR: Oct-1 sense, 5'-ATGAAACTCTGGTCGAAAGACC-3'; Oct-1 antisense, 5'-GATGGAGATGTCCAAGGAAAGC-3'; TRIM21 sense, 5'-GTGCCGAGGAGTAGGACT-3'; TRIM21 antisense, 5'-CTGAAGATGAGCAGCCAGGATT-3'; GAPDH sense, 5'-AGGGTCGAGTCACAGGATTG-3'; and GAPDH antisense, 5'-GTTGATGGCATGAGTCTGGT-3'.
34. Kim, E. J., Park, J. S. & Um, S. J. UbC9-mediated sumoylation leads to transcriptional repression of IRF-1. Biochem. Biophys. Res. Commun. 377, 952–956 (2008).
35. Yeung, T. M., Gandhi, S. C., Wilding, J. L., Muschel, R. & Bodmer, W. F. Cancer stem cells from colorectal cancer-derived cell lines. Proc. Natl Acad. Sci. USA 107, 3722–3727 (2010).
36. Kreso, A. et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat. Med. 20, 29–36 (2014).
37. Sun, H., Leverson, J. D. & Hunter, T. Conserved function of RNF4 family substrates sumoylation. J. Biol. Chem. 282, 20388–20394 (2007).
38. Yeung, T. M., Gandhi, S. C., Wilding, J. L., Muschel, R. & Bodmer, W. F. B-cell lymphoma. Blood 2081–2090 (2014).
39. Demarque, M. D. et al. SUMOylation by Ubc9 regulates the stem cell compartment and structure and function of the intestinal epithelium in mice. Gastroenterology 140, 286–296 (2011).
40. Prudden, J. et al. SUMO-targeted ubiquitin ligases in genome stability. EMBO J. 26, 4089–4101 (2007).
41. Sun, H., Leversen, J. D. & Hunter, T. Conserved function of RNF4 family proteins in eukaryotes: targeting a ubiquitin ligase to SUMOylated proteins. EMBO J. 26, 4102–4112 (2007).
42. Kreso, A. et al. Uncovering global SUMOylation signaling networks in a site-specific manner. Nat. Struct. Mol. Biol. 21, 927–936 (2014).
43. Sahin, U. et al. Interferon controls SUMO availability via the Lin28 and let-7 axis to impede virus replication. Nat. Commun. 5, 4187 (2014).
44. Hu, Y. & Smyth, G. K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 347, 70–78 (2009).
45. Kar, A. K., Diaz-Griffero, F., Li, Y., Li, X. & Sodroski, J. Biochemical and biophysical characterization of a chimeric TRIM21-TRIM5alpha protein. J. Virol. 82, 11669–11681 (2008).
46. Choi, H. K. et al. SUMO-dependent regulation of TBL1-TBLR1 regulates beta-catenin-mediated Wnt signaling. Mol. Cell 43, 203–216 (2011).
47. Luo, J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835–848 (2009).

Acknowledgements
We thank the City of Hope Core facilities, including the Animal Model Core, and Light Microscopy Digital Imaging Core and Pathology Core for excellent technical support. Research reported in this publication also included work performed in the Analytical Cytometry and Integrative Genomics Cores supported by the National Cancer Institute of the National Institutes of Health under award number P30CA033572. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Yuan Chen also received support through NIH grants R01GM086171 and R01GM102538. We also thank Dr Yu Zhou, Ebrahim Zandi for mass spectrometry analysis.

Author contributions
L.D. designed and conducted cellular and mouse model studies; Y.-J.L. provided stable cell lines; M.F. provided human colorectal cancer PDX tissues; R.L.W., M.D., Z.C., P.C. and J.G.-A. obtained human colorectal cancer tissues, matched controls before and after chemoradiation and performed IHC staining and gene expression analysis; Y.C. supervised the project and wrote the manuscript along with all co-authors.

Additional information
Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications

Competing financial interests: Y.C. holds equity in SUMO Biosciences, Inc. The remaining authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

How to cite this article: Du, L. et al. Role of SUMO activating enzyme in cancer stem cell maintenance and self-renewal. Nat. Commun. 7:12326 doi: 10.1038/ncomms12326 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/